Press release
Fibromyalgia Therapeutic Pipeline Analysis, 2022 | Insights into the Latest FDA, EMA, and PMDA Approvals, Clinical/Non-Clinical Trial Activities, Emerging Therapies, and Key Companies by DelveInsight
Fibromyalgia Therapeutic Pipeline
"Fibromyalgia Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Fibromyalgia Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Fibromyalgia Pipeline Analysis
The report provides insights into:
- The report provides detailed insights into the key companies that are developing therapies in the Fibromyalgia Market.
- The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Fibromyalgia treatment.
- It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Fibromyalgia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/fibromyalgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Fibromyalgia Therapeutics Analysis
Fibromyalgia is a long-term (chronic) condition that can cause pain in the muscles and bones (musculoskeletal pain), areas of tenderness, general fatigue, and sleep and cognitive disturbances. The U.S. Food and Drug Administration has approved three drugs to treat fibromyalgia. They include two drugs that change some of the brain chemicals (serotonin and norepinephrine) that help control pain levels: duloxetine (Cymbalta) and milnacipran (Savella).
The other drug approved for fibromyalgia is pregabalin (Lyrica). Pregabalin and another drug, gabapentin (Neurontin), work by blocking the overactivity of nerve cells involved in pain transmission. These medicines may cause dizziness, sleepiness, swelling, and weight gain. To further improve the treatment scenario, globally, several key companies are actively working in the therapeutics market.
As per DelveInsight's assessment, there are approx. 15+ key companies which are developing therapies for Fibromyalgia. Currently, Tonix Pharmaceuticals is leading the therapeutics market with its Fibromyalgia drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Fibromyalgia Therapeutics Market Include
- Tonix Pharmaceuticals
- Aptinyx
- Virios Therapeutics, Inc.
- Teva Pharmaceuticals
- Knop Laboratorios
- ntegrated Tissue Dynamics, LLC
- Axsome
- Sorrento Therapeutics
- Imbrium Therapeutics
- Cytocom Inc.
- Cortene Inc.
- Intec Pharma
- Luye Pharma
And Many Others.
Fibromyalgia Emerging Drugs Covered in the Report Include:
- IMC1: Virios Therapeutics
- TNX-102: Tonix Pharmaceuticals
And Many More
Download Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/fibromyalgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Fibromyalgia Current Treatment Patterns
4. Fibromyalgia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Fibromyalgia Late-Stage Products (Phase-III)
7. Fibromyalgia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Fibromyalgia Discontinued Products
13. Fibromyalgia Product Profiles
14. Fibromyalgia Key Companies
15. Fibromyalgia Key Products
16. Dormant and Discontinued Products
17. Fibromyalgia Unmet Needs
18. Fibromyalgia Future Perspectives
19. Fibromyalgia Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Request the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/fibromyalgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/fibromyalgia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Fibromyalgia Therapeutic Pipeline Analysis, 2022 | Insights into the Latest FDA, EMA, and PMDA Approvals, Clinical/Non-Clinical Trial Activities, Emerging Therapies, and Key Companies by DelveInsight here
News-ID: 2836141 • Views: …
More Releases from DelveInsight Business Research
DelveInsight Enables Strategic Partner Identification for Oncology Biopharma Adv …
DelveInsight, a leading life science market research and strategic consulting firm, today announced the successful completion of a comprehensive Partner Identification and Assessment Program for a US-based mid-sized pharmaceutical company developing a novel clinical-stage oncology asset targeting Head and Neck Cancer. The engagement focused on identifying co-development and commercialization partners across the United States and European markets to accelerate late-stage clinical progress and market entry.
Discover how your oncology asset can…
DelveInsight Facilitates Global Out-Licensing Opportunity for Proprietary Neonat …
DelveInsight Business Research LLP, a leading healthcare strategic intelligence and consulting firm, today announced the successful completion of an out-licensing opportunity assessment for a Sweden-based biopharmaceutical innovator specializing in high-quality neonatal mesenchymal stem cells (MSCs). The engagement was focused on identifying global licensing partners with strong commercialization capabilities, with a strategic emphasis on Asia-Pacific expansion, where regenerative medicine markets are witnessing accelerated regulatory support and clinical adoption.
The client, a clinical-stage…
Yellow Fever Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluat …
(Las Vgas, Nevada, United States) As per DelveInsight's assessment, globally, Yellow Fever pipeline constitutes 3+ key companies continuously working towards developing 3+ Yellow Fever treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Yellow Fever Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers…
Influenza A Infections Market Positioned for Accelerated Development Through 203 …
The Influenza A Infections market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Influenza A Infections pipeline products will significantly revolutionize the Influenza A Infections market dynamics.
DelveInsight's "Influenza A Infections Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Influenza A Infections, historical and forecasted epidemiology as well as the Influenza A…
More Releases for Fibromyalgia
Government Initiatives On Musculoskeletal Health Propel Growth In The Fibromyalg …
The Fibromyalgia Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Fibromyalgia Treatment Market?
The market for the treatment of fibromyalgia has been expanding consistently in past years. At a compound annual growth rate (CAGR) of 3.9%, it is…
SN Clinic's Effective Treatment of Fibromyalgia Symptoms
Image: https://www.globalnewslines.com/uploads/2025/02/1740408683.jpg
SN Clinic Logo
Fibromyalgia can be a debilitating condition, but SN Clinic offers hope through innovative treatments like MLS Laser Therapy and complementary massage therapies. By addressing chronic pain through a holistic approach, patients can experience significant relief and an improved quality of life.
What is Fibromyalgia and What Does Current Data Say?
Fibromyalgia is a chronic condition characterized by widespread musculoskeletal pain, fatigue, and tenderness in localized areas. Affecting…
Prominent Fibromyalgia Treatment Market Trend for 2025: Market Leaders Focus On …
What Are the Projected Growth and Market Size Trends for the Fibromyalgia Treatment Market?
The Fibromyalgia Treatment market is expected to grow from $2.79 billion in 2024 to $2.9 billion in 2025, at a CAGR of 3.9%. This growth is attributed to the increasing prevalence of fibromyalgia, greater awareness about the condition, government initiatives, and rising disposable incomes.
The fibromyalgia treatment market is projected to see steady growth, reaching $3.45 billion by…
Advancements in Fibromyalgia Treatments Driving Market Expansion
The fibromyalgia treatment market is experiencing a steady upward trajectory, with significant growth expected over the next decade. Estimated at USD 2.77 billion in 2023, the market is projected to reach approximately USD 4.13 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.3% from 2024 to 2032. This expansion is driven by several key factors, including advances in treatment options, increasing demand for effective therapies, and…
Fibromyalgia - Drug Pipeline Landscape, 2022
Fibromyalgia is a is a common chronic syndrome characterized by widespread musculoskeletal pain, fatigue, sleep, memory and cognitive issues.
Researchers reported that repeated nerve stimulation causes the brain and spinal cord of people with fibromyalgia to change. The conditions conditions that may bring on symptoms, such as: stressors, viral infections or other illnesses like arthritis, anxiety, depression, other mood disorders, PTSD.
To know more about Fibromyalgia - Drug Pipeline, visit - https://www.globalinsightservices.com/reports/fibromyalgia-drug-pipeline-landscape-2022/
Fibromyalgia…
Fibromyalgia Treatment Market 2022 | Increased Morbidity of Fibromyalgia Along w …
According to Precision Business Insights (PBI), the latest report, the Fibromyalgia Treatment market is expected to be valued at USD 3,017.9 million in 2022, growing at an 3.8% CAGR from 2022 to 2028. Fibromyalgia treatment market analysis projects that the increased prevalence of fibromyalgia and its related complication compelled the introduction of targeted & precise treatment methods for fibromyalgia. Also, the increase in awareness about fibromyalgia will give the required…
